Paget's Disease (see INDICATIONS AND USAGE): The recommended treatment regimen is 30 mg orally once daily for 2 months. Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For retreatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than 1 course of retreatment. HOW SUPPLIED ACTONEL is available as follows: 5-mg film-coated, oval, yellow tablets with RSN on 1 face and 5 mg on the other. NDC 0149-0471-01 bottle of 30 5-mg film-coated, oval, yellow tablets with RSN on 1 face and 5 mg on the other. NDC 0149-0471-03 bottle of 2000 30-mg film-coated, oval, white tablets with RSN on 1 face and 30 mg on the other. NDC 0149-0470-01 bottle of 30 35-mg film-coated, oval, orange tablets with RSN on 1 face and 35 mg on the other. NDC 0149-0472-01 dose pack of 4 Store at controlled room temperature 20°-25° C (68°-77° F) [See USP]. Sold under U. S. patent No. 5, 583,122; 6, 096,342 and 6,165,513 Mfg. by: Procter & Gamble Pharmaceuticals Cincinnati, OH 45202, or OSG Norwich Pharmaceuticals, Inc. North Norwich, NY 13814 Dist. by: Procter & Gamble Pharmaceuticals, TM Owner Cincinnati, OH 45202 Marketed with: Aventis Pharmaceuticals Inc. Kansas City, MO 64137 | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
